Johnson & Johnson
NYSE: JNJKey stats
Price chart
About Johnson & Johnson
Pharmaceuticals
Company profile
- IPO date
- Sep 25, 1944
- Website
- www.jnj.com
Healthcare peers
How JNJ compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $939.49 | -1.64% | $887.63B | 43.01 |
 ABBV AbbVie Inc. | $207.96 | -2.09% | $367.80B | 87.03 |
 MRK Merck & Co. | $121.44 | -1.01% | $300.20B | 16.45 |
 UNH UnitedHealth Group | $304.35 | -0.83% | $276.23B | 22.91 |
 PFE Pfizer Inc. | $26.93 | -1.07% | $153.07B | 19.70 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Johnson & Johnson's competitive moat is built on its diversified product portfolio across pharmaceuticals, medical devices, and consumer health sectors. This diversification protects J&J from sector-specific downturns and provides a steady revenue stream. In pharmaceuticals, blockbusters like Stelara and Imbruvica drive substantial sales growth. The company’s ability to innovate and expand pipeline capabilities provides a growth driver, evident in its strong R&D spending. Valuation support comes from a solid P/E ratio of 21.43 compared to industry standards, suggesting stability. With a market cap of $574.36B, J&J commands significant market influence, which is appealing for investors seeking steady capital appreciation paired with a dividend yield of 2.1556%.
Bear case
Despite its size and stability, Johnson & Johnson isn't without risks. Legal challenges, particularly product liability litigations, pose potential financial pitfalls. Competition in the pharmaceutical industry is fierce, with rivals constantly developing alternative therapies that could erode J&J's market share. Additionally, the company's growth may be constrained by its mature market positioning, limiting upside potential compared to more nimble competitors. The healthcare sector is also subject to political and regulatory changes that could impact profitability. Any disruption in its supply chain due to geopolitical tensions or pandemic-related challenges could adversely affect operations.
Who should buy JNJ
JNJ is ideal for long-term dividend investors with a 10+ year horizon who want reliable income and steady growth. It's suitable for those with moderate risk tolerance looking for a blue-chip stock to anchor a diversified portfolio. This stock fits well into the core holdings of defensive investors focused on stability rather than high-growth ventures.
Key risks
- Legal liabilities related to product defects and healthcare regulations. - Stiff competition from emerging pharmaceutical companies with innovative technologies. - Potential impacts of healthcare policy and reforms which may affect pricing and reimbursement. - Geopolitical risks and supply chain disruptions affecting global operations.
Where to buy JNJ
Open an account with a broker we've reviewed and start trading Johnson & Johnson today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent JNJ news
Preview a busy week on Wall Street: major bank earnings, PPI inflation data, Fed speakers, and key reports from TSM, Netflix, and PepsiCoâread now.
The choice is based on more than just the dividend payout.
Johnson & Johnson (JNJ) is back in the spotlight after presenting extensive clinical and real world data for its recently FDA approved TECNIS PureSee intraocular lens at the ASCRS 2026 meeting in Washington, DC. See our latest analysis for Johnson & Johnson. Those TECNIS PureSee data arrive at a time when Johnson & Johnson’s share price has shown strong momentum over the past quarter, with a 90 day share price return of 16.67% and a 1 year total shareholder return of 61.54%, even though...
This stock might help you sleep more easily at night.
Preview next weekâs stock market eventsâearnings (GS, JPM, BAC, NFLX), IPOs, dividends, and key dataâwith Wall Street Week Ahead.
Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.
Goldman Sachs will kick off a week of earnings reports as investors watch for impacts of the Iran war and concerns about a potential private-credit meltdown. Netflix and Johnson & Johnson are also on deck to report.
"The idea that everything will finally go right in the Middle East seems like a real stretch to me," Cramer said.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.